二甲双胍与糖尿病患者新冠后重症结局的关系
二甲双胍与全因死亡风险降低相关(aRR 0.61,95%CI 0.51–0.73),可能Long COVID风险略低(aRR 0.87,95%CI 0.81–0.94),临床诊断Long COVID无显著关联(aRR 0.90,95%CI 0.68–1.20)。
要点
- 二甲双胍处方与糖尿病患者COVID-19后全因死亡风险降低相关(aRR 0.61)。
- 二甲双胍与可能Long COVID风险略低相关(aRR 0.87),临床诊断Long COVID无显著关联。
- 研究为回顾性队列,不能确立因果关系,需前瞻性验证。
核心结论
- 二甲双胍处方可能与2型糖尿病成人COVID-19后全因死亡风险降低相关。
- 二甲双胍与可能Long COVID风险略低相关,但与临床诊断Long COVID无显著关联。
研究设计与样本
- 回顾性队列研究,数据来自国家临床队列协作组(N3C)。
- 比较12个月累积Long COVID诊断(ICD-10 U09.9)、可能Long COVID(模型衍生表型)及死亡风险,采用Super Learner和靶向最大似然估计调整协变量。
主要发现
- 二甲双胍处方与COVID-19后全因死亡风险降低相关(aRR 0.61,95%CI 0.51–0.73)。
- 二甲双胍使用者较DPP4i使用者可能Long COVID风险略低(aRR 0.87,95%CI 0.81–0.94)。
- 临床诊断Long COVID风险无显著差异(aRR 0.90,95%CI 0.68–1.20)。
临床怎么用
- 对2型糖尿病合并COVID-19者,二甲双胍处方可能与降低死亡风险相关,可结合临床情况考虑延续使用。
- 对Long COVID的预防作用证据不一致,不建议仅为此目的更改降糖方案。
局限性
- 回顾性队列设计,存在残余混杂可能,不能推断因果关系。
- Long COVID临床诊断依赖ICD-10编码,可能存在漏诊或误分类。
- 可能Long COVID基于模型衍生表型,定义准确性有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
ABSTRACT Aims We evaluated the relationship between metformin, one of the most commonly prescribed medications for individuals with diabetes, and COVID-19 sequelae. Materials and Methods We evaluated a retrospective cohort of individuals in the National Clinical Cohort Collaborative with Type 2 diabetes mellitus and COVID-19 who were prescribed metformin or a dipeptidyl peptidase-4 inhibitor (DPP4i) at least 30 days before the onset of acute COVID-19 between 1 October 2021, and 15 November 2023. We compared the 12-month cumulative incidence of Long COVID diagnosis (ICD-10 U09.9: Post COVID-19 condition, unspecified), probable Long COVID (based on a model-derived phenotype), and mortality between individuals prescribed metformin versus DPP4i. We applied Super Learner and targeted maximum likelihood estimation to obtain risk ratios while adjusting for covariates of interest. Results In our sample of 53 332 individuals with Type 2 diabetes and COVID-19, we found that metformin prescription was associated with a lower risk of all-cause mortality after COVID-19 (adjusted risk ratio [aRR]: 0.61, 95% CI: 0.51, 0.73). We also observed that metformin users, compared to DPP4i users, had a slightly lower risk of probable Long COVID (aRR: 0.87, 95% CI: 0.81, 0.94) but did not detect a significant relationship with the clinically defined outcome of Long COVID diagnosis (aRR: 0.90, 95% CI: 0.68, 1.20). Conclusions These findings support the hypothesis that metformin prescription during acute COVID-19 may be associated with lower mortality among adults with diabetes.
引用
- Diabetes, Obesity and Metabolism:Metformin and Severe Post‐COVID‐19 Outcomes Among Individuals With Diabetes Mellitus
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。